Contingency Management in Addiction Care

Key takeaway

Contingency management is a clinical intervention that gives a tangible incentive only after a specific behavior is verified, such as abstinence, attendance, or taking a medicine as prescribed. SAMHSA highlights it for stimulant use disorder, where no FDA-approved medicine exists. The idea is explained here. A prize system stays with the clinic.

Last updated: Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

You may have heard that treatment can pay you to stay off cocaine or meth, and you want to know whether that is real or a trick. Contingency management is a clinic service. SAMHSA's January 2025 advisory defines it as a health care intervention: a tangible incentive is given only when there is objective evidence that a specific behavior happened. The behaviors it names are abstinence from a specific substance, showing up for treatment, or taking medication as prescribed. If the behavior does not happen, the incentive is withheld or reduced. NIDA's treatment overview uses the same idea in shorter form. Positive reinforcement, such as rewards or privileges, follows remaining drug-free, attending and taking part in counseling, or taking treatment medications as prescribed.

The dollar amounts, the schedule, and any prize procedure belong to a program that is following an evidence-based protocol.

If someone has chest pain, a seizure, slow breathing, or will not wake, call 911. For a mental health crisis, call or text 988.

Why stimulant treatment comes up so often

SAMHSA says contingency management is particularly effective for stimulant use disorders. No medication is approved by the FDA to treat those disorders. The advisory, citing SAMHSA's 2024 figures, says more than 4 million people meet criteria for a stimulant use disorder, meaning a disorder involving cocaine, methamphetamine, or prescription stimulants. In that setting SAMHSA calls contingency management a primary intervention, and potentially life-saving. That is a statement about the evidence and the size of the problem. It is not a guarantee for one person.

The same advisory says the approach is equally effective for people who have a stimulant disorder and an opioid disorder together, and for promoting abstinence from cannabis. When both stimulants and opioids are in the picture, the focus might be the stimulant, or it might be sticking with medication for opioid use disorder. SAMHSA also says it has improved attendance and medication adherence among people receiving that medication.

NIDA's principles guide reports a matching finding from studies in methadone programs and in counseling programs: incentive-based interventions are highly effective at keeping people in treatment and promoting abstinence. NIDA describes voucher and prize versions. The values, the number of chances, and the reset rules are clinical protocol. Copying them from a summary is not how a safe program is built.

SAMHSA cites research showing a benefit that lasted a median of 24 weeks after the incentives ended, beyond other active treatments such as cognitive behavioral therapy, 12-step facilitation, and community intensive outpatient care. Most models described in the literature run about three months. Some studies show benefit from a longer course, up to a year, for certain groups. Duration is a clinical and funding decision. It is not a number you set for yourself.

The Department of Veterans Affairs has included contingency management among treatment options since 2011. SAMHSA reports that more than 100 VA medical centers have made it available and that more than 6,000 people have received it. The veterans guide covers VA and other care. Availability at one medical center is a question for that center.

What a patient should expect the rules to protect

SAMHSA's advisory governs grants that are allowed to pay for this service. It does not turn every clinic into a contingency management program, and it does not by itself authorize a new one. A grantee has to confirm with its government project officer that the grant terms include the service.

Where those rules apply, several limits are meant to protect patients:

Incentives are items, or vouchers or gift cards for items and services, that support well-being and recovery. Cash is not permitted.
Each patient in the intervention must have an equal chance to receive the same incentive amounts.
The yearly total SAMHSA allows on those grants is up to $750 per patient. Older SAMHSA funding notices capped the yearly total at $75. The higher figure applies only after the grant terms are updated. It is a ceiling for eligible grantees, not a benefit you are owed, and not a shopping list.
The minimum duration under the grant rules is 12 weeks.
Recipients must be 18 or older.
A health care practitioner authorized to provide substance use treatment in that state verifies the behavior and provides the incentive. Peer specialists are not permitted to deliver contingency management under these rules. They can still provide other peer services the state allows.
People must not be recruited into a clinic specifically for this service or with a promise of incentives. SAMHSA says it should not be used to advertise a practice.
Incentives are furnished immediately after the behavior is verified. Immediacy is part of why the method works. A gift card promised for next month is a different arrangement.

NIDA's 2018 guide still describes a prize model that can involve cash. SAMHSA's 2025 grant rules do not. If a program mentions prizes, ask whether cash is involved and whose rules govern the incentives. Do not treat a social-media version of a prize bowl as the treatment.

When abstinence is the behavior being reinforced, SAMHSA permits that use only for stimulant use disorders or cannabis use disorders. The check is an in-person rapid test. The advisory says cannabis testing can stay positive for a long time during chronic use, which complicates early abstinence incentives, and that breath tests for alcohol detect too short a window to use abstinence as the incentive for alcohol use disorder. Attendance can still be reinforced, where a grant allows, for stimulant, opioid, cannabis, alcohol, or tobacco treatment. Adherence to long-acting injectable buprenorphine or naltrexone, and to long-acting injectable naltrexone for alcohol, can also be the behavior.

SAMHSA is explicit that these services should not be used to promote abstinence from opioids. Rapid tests do not reliably identify fentanyl and related drugs, and they do not reliably separate medications used to treat opioid use disorder from other opioids. There is also a safety reason. As people go longer without opioids, tolerance drops, and a return to use is more likely to cause overdose. Medication for opioid use disorder remains the standard. The medication guide explains methadone, buprenorphine, and naltrexone without doses. An incentive program that tells you to stop those medicines is not following this advisory.

It is an add-on, not the whole plan

SAMHSA says contingency management is most often provided with other treatment, and that grantees should offer it alongside other services that fit the people they serve. It can strengthen motivation to take part in care, or support abstinence, especially for stimulant use disorders. It does not erase the need for counseling, housing help, or medical care. The CBT guide covers one of the therapies often in the same building. Motivational interviewing works from a person's own reasons to change. Contingency management works from a verified behavior and an external incentive. A program can use both. It should not pretend they are the same conversation.

SAMHSA also says that where this care is used with American Indian and Alaska Native communities, leaders and clients should be able to shape protocols that fit community norms. The cocaine guide and the methamphetamine guide cover those substances. The cannabis guide covers cannabis use disorder. The counseling model that pairs lifestyle changes with an incentive is the community reinforcement approach.

Questions worth asking before you enroll

What exact behavior earns an incentive, and how is it verified?
Are the incentives items, vouchers, or gift cards, and is cash excluded?
Who hands them out, and are they a clinician authorized in this state?
Is opioid medication still in the plan if opioids are part of the problem?
How long does the incentive period last, and what care continues after it?

Search FindTreatment.gov and ask whether contingency management is actually offered, not only whether a website uses the phrase. Call or text (800) 653-9376 to ask about programs and whether medication and counseling are on the same plan.

Additional Resources

Sources cited on this page:

Common Questions

Is contingency management the same as a reward chart at home?

No. SAMHSA defines it as a health care intervention. A clinician verifies a specific behavior, then provides an incentive immediately. Under SAMHSA grant rules, a practitioner authorized to provide substance use treatment in that state does this work. Peer specialists are not permitted to deliver it. A homemade chart, a parent's prize jar, or an app you invent is not the treatment.

Does it replace medication for opioid use disorder?

No. SAMHSA says medication for opioid use disorder remains the standard of care, and that its grant rules do not use contingency management to push abstinence from opioids. Tolerance falls during abstinence, which raises overdose risk if use returns, and common rapid tests do not reliably catch fentanyl or separate treatment medicines from other opioids. The same advisory says incentives may be used, where a grant allows, to support attendance or adherence to long-acting injectable buprenorphine or naltrexone.

Why do people mention it for cocaine or methamphetamine?

SAMHSA says it is particularly effective for stimulant use disorders, and that no FDA-approved medicine treats those disorders. The advisory, citing SAMHSA's 2024 figures, says more than 4 million people meet criteria for a stimulant use disorder involving cocaine, methamphetamine, or prescription stimulants. NIDA's principles guide also reports that incentive-based care increases retention and abstinence in studies. That is why the cocaine and methamphetamine guides point here.

Will the program hand me cash?

Not under SAMHSA's 2025 grant advisory. Incentives are supposed to be items, or vouchers or gift cards for items and services, that support well-being and recovery. Cash payments are not permitted. NIDA's 2018 principles guide describes an older prize version that can involve cash. Ask which rules the program follows. Prize amounts and draw schedules stay with the clinic.

Can every clinic offer it, and is there an age limit?

No. SAMHSA says not every grant allows these services, and the advisory does not authorize new programs by itself. A grantee has to confirm terms with its project officer. When those grant rules apply, recipients must be 18 or older, the intervention lasts at least 12 weeks, and each patient must have the same chance at the same incentive amounts. Other payers can have other rules. Ask before you count on an incentive.